Loading...
Loading...
- Eagle Pharmaceuticals Inc's EGRX Q4 FY21 sales declined 15% Y/Y to $42.3 million, missing the consensus of $51.08 million.
- The sales declined primarily due to lower product sales of Belrapzo and Ryanodex and lower royalty revenue of Bendeka, partially offset by higher product sales of Treakisym.
- Q4 2021 Belrapzo sales were $5.5 million, compared to $10.2 million a year ago. Q4 2021 Ryanodex sales declined from $7.9 million to $6.1 million.
- The gross margin was 71%, down from 75% a year ago, driven by revenue mix.
- The Company posted Q4 adjusted EPS of $0.85, missing the consensus of $0.94, and down from $0.96 million a year ago.
- Cash and cash equivalents were $97.7 million, and debt was $26.0 million as of December 31, 2021.
- Guidance: Eagle Pharma expects Q1 FY22 sales of $120 million - $130 million, with adjusted EPS of $3.80 - $4.10.
- Price Action: EGRX shares traded 2.57% higher at $46.26 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in